Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.

Publication ,  Journal Article
Salvaggio, G; Furlan, A; Agnello, F; Cabibbo, G; Marin, D; Giannitrapani, L; Genco, C; Midiri, M; Lagalla, R; Brancatelli, G
Published in: Radiol Med
April 2014

PURPOSE: This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment. METHODS AND MATERIALS: Seventeen patients (12 men, 5 women; mean age 69 years; age range 58-79 years) were included. Tumour response was assessed according to RECIST and mRECIST. Two readers placed a region of interest (ROI) within each target lesion, on the portion showing enhancement during the arterial phase. The lesion attenuation values measured within the ROIs on computed tomography or the signal intensity measured on magnetic resonance imaging, during the unenhanced phase, hepatic arterial phase and venous phase were recorded. Changes in arterial and venous contrast enhancement before and after treatment were compared among the mRECIST groups using Mann-Whitney U test. RESULTS: Agreement between mRECIST and RECIST was good (Cohen's k coefficient, 0.791). Patients with partial response had a greater decrease in arterial enhancement (-79.8%) than did patients with stable disease (SD) (-24.8%; p = 0.011) or progressive disease (PD) (-32.9%; p = 0.034). No statistically significant difference in arterial enhancement variation was found among patients with SD and PD. No statistically significant difference in venous enhancement was found among the mRECIST groups. CONCLUSIONS: mRECIST showed a more favourable response compared to RECIST 1.1 in patients with unresectable HCC receiving sorafenib.

Duke Scholars

Published In

Radiol Med

DOI

EISSN

1826-6983

Publication Date

April 2014

Volume

119

Issue

4

Start / End Page

215 / 221

Location

Italy

Related Subject Headings

  • Treatment Outcome
  • Tomography, X-Ray Computed
  • Sorafenib
  • Phenylurea Compounds
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Niacinamide
  • Middle Aged
  • Meglumine
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Salvaggio, G., Furlan, A., Agnello, F., Cabibbo, G., Marin, D., Giannitrapani, L., … Brancatelli, G. (2014). Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol Med, 119(4), 215–221. https://doi.org/10.1007/s11547-013-0332-5
Salvaggio, Giuseppe, Alessandro Furlan, Francesco Agnello, Giuseppe Cabibbo, Daniele Marin, Lydia Giannitrapani, Chiara Genco, Massimo Midiri, Roberto Lagalla, and Giuseppe Brancatelli. “Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.Radiol Med 119, no. 4 (April 2014): 215–21. https://doi.org/10.1007/s11547-013-0332-5.
Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, et al. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol Med. 2014 Apr;119(4):215–21.
Salvaggio, Giuseppe, et al. “Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.Radiol Med, vol. 119, no. 4, Apr. 2014, pp. 215–21. Pubmed, doi:10.1007/s11547-013-0332-5.
Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol Med. 2014 Apr;119(4):215–221.
Journal cover image

Published In

Radiol Med

DOI

EISSN

1826-6983

Publication Date

April 2014

Volume

119

Issue

4

Start / End Page

215 / 221

Location

Italy

Related Subject Headings

  • Treatment Outcome
  • Tomography, X-Ray Computed
  • Sorafenib
  • Phenylurea Compounds
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Niacinamide
  • Middle Aged
  • Meglumine
  • Male